FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 07/2023”. The Monitor is a month-to-month revealed overview of enterprise capital traits within the European Life Sciences sector.
As of the tip of July 2023 we establish the next present VC traits in Europe:
- In 2023, total Life Sciences funding has reached EUR 5,325m
- Biotech acquired 46% of the full funding quantity (-1% in comparison with the earlier month)
- Oncology dominates as the highest indication in Biotech
- Tenpoint Therapeutics (United Kingdom) has the very best transaction quantity of EUR 64m in July, adopted by Neko Well being (Sweden) EUR 60 and Causaly (United Kingdom) EUR 55m
- The European Innovation Council Fund (Belgium) dominates the High 5 Buyers (by deal quantity), adopted by Revival Healthcare Capital (United States) and Gilde Healthcare Companions (Netherlands)
- High 5 Offers exceed EUR 130m every, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To entry the total report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marco Buonafede-Bennardo.